Compare MSBI & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | MDXG |
|---|---|---|
| Founded | 1881 | 2006 |
| Country | United States | United States |
| Employees | 861 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.1M | 530.2M |
| IPO Year | N/A | 2007 |
| Metric | MSBI | MDXG |
|---|---|---|
| Price | $27.69 | $3.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $24.33 | $9.00 |
| AVG Volume (30 Days) | 133.7K | ★ 1.7M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $2.07 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $14.24 | $3.03 |
| 52 Week High | $28.53 | $7.99 |
| Indicator | MSBI | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 49.42 |
| Support Level | $26.20 | $3.45 |
| Resistance Level | $28.53 | $7.39 |
| Average True Range (ATR) | 0.71 | 0.12 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 65.78 | 51.43 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.